Watch CHRS. Know when insiders buy.
One email the day a filing lands. Free.
CHRS
Coherus Oncology, Inc.
1.32
−0.05 −3.65%
USD · close Sep 9
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
56
WATCH · shorts 56
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $203.9MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$132.1M −173.5%NET CASH $9.3M52W 1.10 – 2.51SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$32.3M | −$20.6M | −106.9% | -0.13 | −$62.1M | — | — | Aug 5 |
| Q1 2026 · Mar 31 | — | — | — | −$36.2M | −$38.3M | — | -0.28 | −$57.9M | — | — | Aug 5 |
| Q4 2025 · Dec 31derived | — | — | — | −$45.9M | −$37.6M | — | -0.34 | −$19.7M | — | — | Mar 9 |
| Q3 2025 · Sep 30 | — | — | — | −$44.3M | −$35.5M | — | -0.31 | −$46.3M | — | — | Nov 6 |
| Q2 2025 · Jun 30 | — | — | — | −$45.5M | $297.8M | — | 2.57 | −$46.6M | — | — | Aug 5 |
| Q1 2025 · Mar 31 | — | — | — | −$45.4M | −$56.6M | −155.0% | 2.57 | −$25.8M | — | — | Aug 5 |
| Q4 2024 · Dec 31derived | — | — | — | −$45.4M | −$50.7M | — | -0.44 | $28.6M | — | — | Mar 9 |
| Q3 2024 · Sep 30 | — | — | — | −$46.9M | −$10.8M | — | -0.09 | −$62M | — | — | Nov 6 |
| Q2 2024 · Jun 30 | — | — | — | −$39.6M | −$12.9M | — | -0.11 | $59.7M | — | — | Nov 6 |
| Q1 2024 · Mar 31 | — | — | — | −$67.8M | $102.9M | — | 0.91 | −$46.8M | — | — | Nov 6 |
| Q4 2023 · Dec 31derived | — | — | — | −$68.9M | −$79.7M | — | -0.74 | −$12.9M | $34K | −$13M | Mar 17 |
| Q3 2023 · Sep 30 | — | — | — | −$32M | −$39.6M | — | -0.41 | −$54.3M | $0 | −$54.3M | Nov 6 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$181.1M | $168M | — | 1.43 | −$138.5M | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$199.7M | $28.5M | — | 0.25 | −$20.4M | — | — | — | — |
| FY2023 · to Dec 31 | — | — | −$203.2M | −$237.9M | — | -2.53 | −$174.9M | $286K | −$175.2M | — | — |
| FY2022 · to Dec 31 | — | — | −$256.9M | −$291.8M | — | -3.76 | −$241.1M | $2M | −$243.2M | — | — |
| FY2021 · to Dec 31 | — | — | −$263.9M | −$287.1M | — | -3.81 | −$37.4M | $1.3M | −$38.7M | — | — |
| FY2020 · to Dec 31 | — | — | $156.3M | $132.2M | — | 1.62 | $154.1M | $7.2M | $146.9M | — | — |
Every number comes from Coherus Oncology, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.